Groovy Medicine Secures Tens of Millions of RMB in Strategic Financing Round to Accelerate Pipeline Clinical Development
Groovy Medicine recently announced the completion of tens of millions of yuan in a strategic round of financing. This round was led by Xinghua Dingli, with participation from Hangzhou Science and Technology Innovation Group’s Disruptive Technology Achievement Transformation Fund and Hangzhou Talent Fund. The funds will be used to advance clinical trials for the GW-01 pipeline and accelerate the discovery of more innovative targets on Groovy platform, as well as expand external collaboration.
Professor Li Xu, Founder of Groovy Medicine, stated: “We sincerely thank both new and existing investors for their recognition and support. Leveraging our unique high-dimensional biology platform, the company has established multiple innovative pipelines with First-in-Class potential. Among these, our core pipeline GW-01 has basically completed preparations for its IND (Investigational New Drug) application and will enter the clinical trial phase in the near term. Since its establishment, Groovy Medicine has brought together a professional, efficient, and collaborative R&D and operations team, and the value of our platform and progress of our pipelines have attracted broad attention from pharmaceutical companies at home and abroad. By continuously integrating cutting-edge resources and pooling industry expertise, Groovy Medicine will further enhance the accuracy and efficiency of target discovery, injecting new vitality into traditional drug R&D pathways.”
He Jionglin, Investment Director of Xinghua Dingli, commented: “We firmly believe that innovative drug discovery driven by data and algorithms is a key force in breaking through traditional R&D bottlenecks and leading the transformation of the pharmaceutical industry. The Groovy Medicine team not only possesses profound insights into biological challenges but has also built unique and solid underlying data barriers and algorithm models. They are committed to revolutionizing the paradigm of drug discovery from its roots. We are optimistic about their great potential to grow into a next-generation biotech platform company and look forward to collaborating with them to deliver breakthrough treatment options to patients worldwide.”
About Xinghua Dingli
Founded in 2022, Xinghua Dingli is an emerging professional investment institution focusing on the biomedical, new energy, and pan-semiconductor sectors. Upholding the philosophy of “leading investments, substantial investments, and follow-up investments,” it is dedicated to identifying and supporting outstanding entrepreneurs who consistently create value. Currently, Xinghua Dingli manages a fund size of 1 billion RMB and has invested in over 20 high-quality enterprises, with multiple projects entering the IPO application stage. It has won honors including “2022 Zhejiang Emerging Venture Capital Institution,” “Invest China 2023 Top 5 Emerging Venture Capital Institutions,” “Golden Investment Award 2024 Top 10 Emerging VC Institutions in China,” “Invest China 2024 Top 5 Emerging Early-Stage Investment Institutions,” and “Golden Investment Award 2025 Top 10 Emerging Investment Institutions in China.”
About Hangzhou Talent Fund
Hangzhou Talent Fund is a “patient capital” entity focused on investing in talent-driven innovation and entrepreneurship projects. Its first-phase direct investment fund has a scale of 1 billion RMB and is operated and managed by Hangzhou Talent Group. The fund focuses on the integrated coordination of “talent + technology + industry” and full-cycle cultivation, concentrating on talent innovation, entrepreneurship, and the transformation of scientific and technological achievements to empower the entire growth lifecycle of high-level talent projects in Hangzhou. Since officially launching its investment activities in January 2025, Hangzhou Talent Fund has adhered to the principle of “investing early, investing in small enterprises, investing in talent, and investing in technology,” having invested in over 20 high-quality enterprises and continuously supporting Hangzhou in building a city with the optimal talent ecosystem.
About Hangzhou Science and Technology Innovation Group
Hangzhou Science and Technology Innovation Group is a wholly-owned subsidiary of Hangzhou State-Owned Capital Investment and Operation Co., Ltd., dedicated to being a discoverer and nurturer of innovative value. It manages and operates the “Hangzhou Science and Technology Innovation Fund” with a scale of 100 billion RMB, having invested in over 2,400 enterprises, cumulatively fostering 120 listed companies, and incubating high-tech, high-growth enterprises such as the “Six Little Dragons” (including Yushu Technology, BrainCo, and CloudMinds). The Hangzhou Runmiao Fund and the Disruptive Technology Achievement Transformation Fund,specifically managed by Hangzhou Science and Technology Innovation Group,aim to identify and invest in a portfolio of forward-looking, leading, and disruptive technological achievements, nurturing these initiatives, accompanying their growth, and supporting the development of new quality productive forces.